Phase II Trial of GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
Price : $35 *
At a glance
- Drugs GDC 0084 (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Therapeutic Use
- 12 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Feb 2019 Planned initiation date changed from 31 Dec 2018 to 28 Feb 2019.
- 04 Dec 2018 Status changed from planning to not yet recruiting.